BioArctic Achieves Significant Milestone with Orphan Drug Designation
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) recently announced that the US FDA has granted orphan drug designation to exidavnemab for treating Multiple System Atrophy (MSA). This designation offers critical incentives aimed at developing treatments for rare diseases that have a considerable medical necessity.
Understanding Multiple System Atrophy
Multiple System Atrophy (MSA) is a devastating and progressively fatal condition affecting both the central and autonomic nervous systems. The disease is marked by the accumulation of alpha-synuclein proteins, leading to the gradual deterioration of brain nerve cells. Hence, individuals affected by MSA experience severe impairments in balance, movement, and various autonomic functions including breathing, digestion, and bladder control. As of now, effective treatments to halt its progression remain elusive.
Innovative Approach with Exidavnemab
Exidavnemab is being explored as an innovative disease-modifying treatment for synucleinopathies, which encompass conditions like MSA and Parkinson's disease. This monoclonal antibody selectively targets soluble alpha-synuclein aggregates, such as oligomers and protofibrils. By facilitating the clearance of these aggregates, exidavnemab aims to mitigate the spread of the harmful alpha-synuclein and support the preservation of neuronal function, potentially slowing disease progression.
Regulatory Support for Research and Development
The FDA's Orphan Drug Designation program is crucial as it provides support for drugs intended to treat conditions that affect fewer than 200,000 individuals in the United States. Those who receive this designation benefit from various incentives, including tax credits for qualifying clinical trials, waivers for certain user fees, and the possibility of seven years of exclusive marketing rights after receiving FDA approval.
Continued Commitment to Patients with MSA
MSA presents a high unmet medical need with a dire prognosis. Many patients endure only 6 to 10 years following the onset of symptoms, and only a handful live beyond 15 years. The detrimental effects of MSA classify it as a rare yet profoundly challenging condition, impacting under 42,000 individuals across the nation.
About Exidavnemab's Mechanism
This monoclonal antibody drug candidate is designed to specifically target and remove aggregated forms of alpha-synuclein, which play a significant role in neurodegenerative diseases like MSA and Parkinson's disease. The goal is to create a treatment that halts or significantly slows down the decline associated with these conditions.
BioArctic’s Mission and Innovations
BioArctic AB (publ) is a pioneering Swedish biopharmaceutical company dedicated to developing innovative therapies that challenge the progression of neurodegenerative diseases. Among its notable contributions is Leqembi® (lecanemab), the first drug proven to decelerate Alzheimer’s disease and mitigate cognitive decline in its early stages. This product has been developed in collaboration with Eisai. Furthermore, BioArctic showcases a diverse research agenda focusing on Alzheimer’s, Parkinson’s, ALS, and enzyme deficiency diseases, leveraging cutting-edge technology such as the proprietary BrainTransporter™ that enhances drug delivery to the brain.
Frequently Asked Questions
What is Orphan Drug Designation?
The Orphan Drug Designation is a status granted by the FDA to encourage the development of treatments for rare diseases affecting fewer than 200,000 individuals in the U.S.
What is Multiple System Atrophy (MSA)?
MSA is a rapidly progressing and fatal rare disease that affects the central and autonomic nervous systems, marked by the aggregation of alpha-synuclein proteins.
How does exidavnemab work?
Exidavnemab is designed to selectively target and eliminate aggregated alpha-synuclein, aiding in the preservation of neuronal function and potentially slowing the disease's progression.
What incentives does the Orphan Drug Designation provide?
Incentives include tax credits for clinical trials, exemptions for user fees, and potential seven-year marketing exclusivity upon FDA approval.
What is BioArctic's role in neurodegenerative disease treatment?
BioArctic is focused on pioneering new treatments for neurodegenerative diseases, contributing to efforts such as Leqembi for Alzheimer's, and exploring pathways for conditions like MSA with exidavnemab.
